You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 4,937,182


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,937,182
Title: Method for predicting chemosensitivity of anti-cancer drugs
Abstract:An assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.
Inventor(s): Hancock; Miriam E. C. (Oakland, CA), Smith; Helene S. (Oakland, CA), Hackett; Adeline J. (Orinda, CA)
Assignee: Peralta Cancer Research Institute (San Leandro, CA)
Application Number:07/307,552
Patent Claims:1. An assay for determining drug sensitivity of a neoplasm wherein the neoplasm cells are not separated into single cells and cultured, said assay comprising:

dissecting the neoplasm and fragmenting it into small clumps to form organoids;

suspending the organoids into a growth medium and allowing the organoid cells to grow;

harvesting the organoid cells and then exposing the organoid cells which have not been cultured from a single cell, to a drug to be assayed; and

determining the sensitivity of the organoid cells to the drug.

2. The assay of claim 1, wherein the organoids are substantially free from attached stromal elements before suspension into the growth medium.

3. The assay of claim 1, wherein the small clumps are fragmented into organoids by contacting the small clumps with at least one proteinase.

4. The assay of claim 3, wherein the proteinase is collagenase.

5. The assay of claim 3, wherein the proteinase is hyaluronidase.

6. An assay for determining drug sensitivity of a neoplasm wherein the neoplasm cells are not separated into single cells and cultured, said assay comprising:

dissecting and mincing the neoplasm;

breaking down surrounding stromal tissue of the neoplasm to form organoids;

suspending the organoids into a growth medium and allowing the organoid cells to grow;

harvesting the organoid cells and then exposing the organoid cells which have not been cultured from a single cell, to a drug to be assayed; and

determining the sensitivity of the organoid cells to the drug.

7. The assay of claim 6, wherein the organoids are substantially free from attached stromal elements before the organoids are suspended into the growth medium.

8. The assay of claim 6, wherein the small clumps are fragmented into organoids by contacting the small clumps with at least one proteinase.

9. The assay of claim 8, wherein the proteinas is collagenase.

10. The assay of claim 8, wherein the proteinase is hyaluronidase.

11. An assay for determining drug sensitivity of a neoplasm wherein the neoplasm cells are not separated into single cells and cultured, said assay comprising:

dissecting and fragmenting the neoplasm;

subjecting the neoplasm to enzyme digestion until clamps of cells of the neoplasm are observed to be free stromal elements;

collecting the clumps of cells and then suspending the clumps of cells into a growth medium to allow the cells to rapidly proliferate;

harvesting the cells and then exposing the cells which have not been cultured from a single cell, to a drug to be assayed; and

determining the sensitivity of the cells to the drug.

12. The assay of claim 11, wherein the enzyme digestion is performed with proteinases.

13. The assay of claim 11, wherein the enyzyme digestion is performed with collagenase.

14. The assay of claim 11, wherein the clumps of cells are allowed to rapidly proliferate to form a monolayer before they are harvested.

15. The assay of claim 11, wherein the neoplasm is a breast tumor.

16. The assay of claim 11, wherein the enzyme digestion is performed with a mixture of collagenase and hyaluroidase.

17. The assay of claim 11, wherein the clumps of cells are collected such that undesired cellular components are removed.

18. The assay of claim 17 wherein the undesired cellular components are removed by filtration.

Details for Patent 4,937,182

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2007-06-26
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2007-06-26
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2007-06-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.